-+ 0.00%
-+ 0.00%
-+ 0.00%
AstraZeneca China announced today that its 13 innovative drugs will benefit more patients with tumors, respiratory, immune, kidney and rare diseases through the new version of the national basic medical insurance drug catalogue and commercial insurance innovative drug catalogue adjustments. In the new version of the medical insurance catalogue, AstraZeneca introduced 2 innovative drugs for the first time, 5 innovative drugs included for new indications, 4 successfully renewed, and 1 was transferred to conventional category B. In addition, AstraZeneca also has an innovative drug included in the new commercial insurance innovative drug catalogue for the first time. The revised version of the catalogue will be officially implemented on January 1, 2027.
Share
Listen to the news
AstraZeneca China announced today that its 13 innovative drugs will benefit more patients with tumors, respiratory, immune, kidney and rare diseases through the new version of the national basic medical insurance drug catalogue and commercial insurance innovative drug catalogue adjustments. In the new version of the medical insurance catalogue, AstraZeneca introduced 2 innovative drugs for the first time, 5 innovative drugs added new indications, 4 successfully renewed, and 1 was transferred to conventional category B. In addition, AstraZeneca also has an innovative drug included in the new commercial insurance innovative drug catalogue for the first time. The revised version of the catalogue will be officially implemented on January 1, 2027.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending